UNSPSC 51273820: Chloroxylenol/iodine/menthol/potassium iodide/thymol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.

UNSPSC 51273820 Chloroxylenol/iodine/menthol/potassium iodide/thymol is a Commodity code, but the recent state and local opportunities posted under it do not align with its nominal scope — the three recent solicitations instead reflect broader pharmaceutical procurement, including naloxone acquisition, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The code shows little relevant recent activity in its stated therapeutic-antiseptic product category. Issuing bodies using this code span county health departments, state health agencies, and multistate cooperative purchasing alliances. Seminole County, Florida pursued naloxone and drug deactivation systems through competitive bidding (IFB), while the Texas Health and Human Services Commission issued an exploratory RFI on direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by Minnesota's Department of Administration solicited generic pharmaceuticals and OTC products through RFP.

Geographic activity appears concentrated in Florida, Texas, and Minnesota based on recent postings. The Seminole County IFB (number IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with an IFB response deadline of July 26, 2023. The MMCAP RFP (number S1070000015802) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon had a proposal deadline of March 26, 2026, with price competitiveness weighted at 75 percent of evaluation and contract awards effective July 1, 2026. The Texas HHS RFI (number HHS0017013) functioned as a preliminary market-intelligence phase rather than a binding solicitation, seeking vendor capabilities for direct-to-manufacturer prescription contracting with no formal award value disclosed. Code misalignment suggests that vendors pursuing state and local pharmaceutical opportunities should monitor broader generic and OTC drug procurement codes rather than relying on this specific therapeutic-antiseptic classification.